Last reviewed · How we verify
B-MAD chemotherapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
B-MAD chemotherapy (B-MAD chemotherapy) — The Thai Lymphoma Study Group.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| B-MAD chemotherapy TARGET | B-MAD chemotherapy | The Thai Lymphoma Study Group | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- B-MAD chemotherapy CI watch — RSS
- B-MAD chemotherapy CI watch — Atom
- B-MAD chemotherapy CI watch — JSON
- B-MAD chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). B-MAD chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/b-mad-chemotherapy. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab